Blood Substitutes: Possibilities with Nanotechnology

Alam, Feroz; Yadav, Neha; Ahmad, Musheer; Shadan, Mariyam

doi:10.1007/s12288-013-0309-5

Cited by 10 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is well-known that fluorine molecules have excellent oxygen-carrying capacity; in particular, PFC has been developed as a potential blood substitute. , Therefore, the oxygen loading and release of HAFOE-NPs was further evaluated using a dissolved oxygen detector, with PFC and PBS as the controls. As shown in Figure c, the PBS group shows a very low oxygen concentration in deoxygenated water.…”

Section: Results and Discussionmentioning

confidence: 99%

“…Currently, the widely used oxygen-carrying materials are hemoglobin (Hb) and perfluorocarbon (PFC). 26,27 Unfortunately, Hb is very expensive and susceptible to autoxidation with the generation of met-Hb (nonfunctional Hb) and free radicals, 29,30 which limit its potential for large-scale use in clinical practice. Alternatively, PFC is an effective synthetic substitute because its significant advantages include good physiochemical stability, low immunogenicity, excellent oxygen solubility, and lower cost.…”

Section: ■ Introductionmentioning

confidence: 99%

“…To date, various strategies have been explored to modulate tumor hypoxia, such as in situ oxygen regeneration by the decomposition of endogenous hydrogen peroxide (H 2 O 2 ), blood oxygen delivery by an increase in the blood flow, and exogenous oxygen delivery by nanocarriers. − Oxygen supplementation via the first two methods is mainly derived from the body; however, their effectiveness is controversial because of the limited amount of H 2 O 2 and the incompleteness of blood vessels in tumor tissue. , On the contrary, relieving hypoxia by oxygen carriers is considered to be a potentially viable route. Currently, the widely used oxygen-carrying materials are hemoglobin (Hb) and perfluorocarbon (PFC). , Unfortunately, Hb is very expensive and susceptible to autoxidation with the generation of met-Hb (nonfunctional Hb) and free radicals, , which limit its potential for large-scale use in clinical practice. Alternatively, PFC is an effective synthetic substitute because its significant advantages include good physiochemical stability, low immunogenicity, excellent oxygen solubility, and lower cost. − In most cases, PFC as hydrophobic compounds is encapsulated into the core of nanoparticles for relieving tumor hypoxia, such as nanodroplets, hollow magnetic nanoparticles, and lipid nanoparticles. ,, Although these efforts have achieved some progress, there are still a few technical challenges that need attention like low PFC loading, low intracellular accumulation, restricted oxygen release and diffusion, etc. , Therefore, it is necessary to design a suitable nanomaterial or nanoplatform to overcome these adverse effects.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Cisplatin-Cross-Linked and Oxygen-Resupply Hyaluronic Acid-Based Nanocarriers for Chemo-photodynamic Therapy

Cheng

Shi

et al. 2021

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

Tumor microenvironment (TME) is known to play a critical role in cancer progression and contributes to treatment failure or success. Herein, a versatile nanoplatform [HAFOE-Ce6/ Pt-NPs(O 2 )] with cisplatin (Pt) cross-linking, chlorin e6 (Ce6) loading, pH sensitivity, active targeting, and oxygen resupply was developed to address this problem. This nanosystem presents as a spherical shape with a small size of 175.4 ± 2.16 nm and a negative charge of −25.32 ± 3.04 mV. Hyaluronic acid (HA) as the starting material not only improved the biocompatibility of the nanosystem but also enhanced cellular uptake by targeting the CD44 receptor. Interestingly, cisplatin could serve as both a cross-linker and anticarcinogen to increase the blood stability and therapeutic performance. Additionally, the micelles disintegration and drug release could be accelerated by the cleavage of ortho ester at low pH. More importantly, the fluorocarbon inside the particles has the ability to load oxygen and in situ release oxygen at tumor regions, which greatly reduced tumor hypoxia. In vitro and in vivo results demonstrated that HAFOE-Ce6/Pt-NPs(O 2 ) could efficiently inhibit tumor growth by combined chemo-photodynamic therapy under 660 nm laser irradiation by way of oxygen sensitization, leading to a high mice survival rate (83.33%). Overall, this combined nanosystem could take advantage of TME while overcoming its disadvantages and was an efficient nanoplaform for cancer treatment.

show abstract

Section: Results and Discussionmentioning

confidence: 99%

Section: ■ Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cisplatin-Cross-Linked and Oxygen-Resupply Hyaluronic Acid-Based Nanocarriers for Chemo-photodynamic Therapy

Cheng

Shi

et al. 2021

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

show abstract

“…As mentioned earlier, PFC molecules are generally emulsified to form particles (in micro level) and to be used as an oxygen carrier, and the emulsifier eventually decomposes in the body. The oxygen transport of PFC particles was well-known with a linear relationship between PaO 2 and oxygen content, which contrasts with the sigmoidal oxygen dissociation of blood (Alam et al, 2014). Two main advantages of PFC-based oxygen transport to improve efficacy are: (a) PFC particles perfuse in the microcirculation of capillaries where no RBCs may flow; and (b) the oxygen carried by PFC particles is in dissolved state.…”

Section: Nanomedicines For the Gas-carrier Componentmentioning

confidence: 99%

Nanomedicines: A Potential Treatment for Blood Disorder Diseases

Zhang

Wei

2019

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Blood disorder diseases (BDDs), also known as hematologic, is one of the diseases owing to hematopoietic system disorder. Chemotherapy, bone marrow transplantation, and stem cells therapy have been used to treat BDDs. However, the cure rates are still low due to the availability of the right type of bone marrow and the likelihood of recurrence and infection. With the rapid development of nanotechnology in the field of biomedicine, artificial blood or blood substitute has shown promising features for the emergency treatment of BDDs. Herein, we surveyed recent advances in the development of artificial blood components: gas carrier components (erythrocyte substitutes), immune response components (white blood cell substitutes), and hemostasis-responsive components (platelet substitutes). Platelet-inspired nanomedicines for cancer treatment were also discussed. The challenges and prospects of these treatment options in future nanomedicine development are discussed.

show abstract

“…In a rat hemorrhagic shock model (25% blood volume removal under anesthesia, followed by resuscitation with an equal volume of the blood substitute) tissue oxygen levels and hemodynamics were partially reconstituted. For related work see [31,32]. Fibroblast growth factor-2 (FGF2 or bFGF, 'basic FGF') was the first identified member of this extremely diverse family of extracellular regulators that controls the physiology and development of virtually all higher vertebrate tissues, and it remains the best-studied one [33].…”

mentioning

confidence: 99%